The first ten CoreTherm® Eagle machines are manufactured
ProstaLund today announces that the company has reached another important milestone with its new platform, CoreTherm® Eagle, for the treatment of benign prostatic enlargement (BPH/BPE). The first ten machines are now manufactured and launching in the first clinics is expected to take place during the end of the year and the first quarter of 2025.
“This is a significant milestone for ProstaLund. The launch of CoreTherm® Eagle gives us great opportunities to open up new treating clinics, both in the Nordics and internationally”, says Anders Kristensson, CEO of ProstaLund.
The new CoreTherm® Eagle is based on the well-proven and established technology, CoreTherm® Concept, which has been developed and refined over 25 years and has been used for over 30,000 treatments of benign prostate enlargement in the Nordic region. CoreTherm® Eagle has been developed to further simplify the treatment process with updates that make it more intuitive and user-friendly.
CoreTherm® is a fast, safe and effective heat treatment for men with benign prostatic hyperplasia (BPH/BPE). The treatment takes less than 15 minutes and requires no surgical intervention. One of the main advantages of CoreTherm® is the ability to treat virtually all different types of patients. Prostate size is not a limiting factor, even prostate glands over 300 ml have been treated. CoreTherm® is performed with local anesthesia, which eliminates the risks of general anesthesia and allows treatment even of patients deemed unsuitable for general or spinal anesthesia.
“With CoreTherm® Eagle, we can give more clinics an opportunity to offer patients an effective outpatient treatment for benign prostate enlargement. Together we can improve the quality of life for men with prostate problems”, says Anders Kristensson.
